Business
Avacta's CEO to Present at Biotech Investor Day
Avacta's CEO to Present at Biotech Investor Day.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 9227G Avacta Group PLC 29 July 2019 \n\n29 July 2019\nAvacta Group plc\n(\"Avacta\", the \"Company\" or the \"Group\")\n \nAvacta's Chief Executive Officer to Present at the Solebury Trout European Biotech Investor Day in New York\nAvacta Group plc (AIM: AVCT), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, is pleased to announce that its Chief Executive Officer, Dr Alastair Smith, will present at the European Biotech Investor Day in New York City in the New York Times building on Thursday, August 1st organised by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.\nAlastair's presentation will discuss the Company's drug development pipeline based on the combination of Affimer immunotherapies with tumour targeted chemotherapy aimed at addressing the lack of a durable response to current immunotherapies experienced by most cancer patients.\nThe presentation will be made available on the Company's website: https://www.avacta.com/investors/documents.\n- Ends -\n \nFor further information from Avacta Group plc, please contact: \n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\n \n\n\nTel: +44 (0) 844 414 0452\nwww.avacta.com \n\n\n \n\n\n\n\nfinnCap Ltd (Nominated Adviser and Joint Broker)\nGeoff Nash / Giles Rolls - Corporate Finance\nTim Redfern - ECM\n \nWG Partners (Joint Broker)\nNigel Birks / Nigel Barnes\nDavid Wilson / Claes Spang\n \n\n\nTel: +44 (0) 207 220 0500\nwww.finncap.com\n \n \nTel: +44 (0) 203 705 9318\nTel: +44 (0) 203 705 9217\nwww.wgpartners.co.uk\n \n\n\n \n\n\n\n\nTurner Pope Investments\nJames Pope / Ben Turner\n \nYellow Jersey PR (Financial Media and IR)\nSarah Hollins \nHarriet Jackson\n \nZyme Communications (Trade and Regional Media)\nKatie Odgaard\n\n\nTel: +44 (0) 203 621 4120\nwww.turnerpope.com\n \n \nTel: +44 (0)7764 947 137\nTel: +44 (0)7544 275 882\[email protected]\n \nTel: +44 (0)7787 502 947\[email protected]\n\n\n\n\n \n \nAbout Avacta Group plc - https://www.avacta.com\nAvacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeu...